Log in

NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

$56.85
-4.72 (-7.67 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$56.01
Now: $56.85
$60.44
50-Day Range
$55.41
MA: $78.96
$90.19
52-Week Range
$54.24
Now: $56.85
$94.85
Volume422,627 shs
Average Volume355,177 shs
Market Capitalization$2.41 billion
P/E Ratio40.04
Dividend YieldN/A
Beta0.99
Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Read More
Omnicell logo

Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$897.03 million
Cash Flow$3.53 per share
Book Value$20.16 per share

Profitability

Net Income$61.34 million

Miscellaneous

Employees2,700
Market Cap$2.41 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.


Omnicell (NASDAQ:OMCL) Frequently Asked Questions

How has Omnicell's stock been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMCL shares have decreased by 26.6% and is now trading at $56.85. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omnicell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Omnicell.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, February, 6th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.78 by $0.01. The company had revenue of $248.29 million for the quarter, compared to the consensus estimate of $243.69 million. Omnicell had a net margin of 6.84% and a return on equity of 11.76%. Omnicell's revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 EPS. View Omnicell's earnings history.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of $2.96-3.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.00-1.02 billion, compared to the consensus revenue estimate of $991.00 million.

What price target have analysts set for OMCL?

7 analysts have issued 12 month target prices for Omnicell's stock. Their forecasts range from $82.00 to $100.00. On average, they expect Omnicell's stock price to reach $89.29 in the next year. This suggests a possible upside of 57.1% from the stock's current price. View analysts' price targets for Omnicell.

Has Omnicell been receiving favorable news coverage?

Press coverage about OMCL stock has been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Omnicell earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutOmnicell.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Netflix (NFLX), Johnson & Johnson (JNJ), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD) and QUALCOMM (QCOM).

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
  • Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (3.76%), Credit Suisse AG (3.51%), State Street Corp (2.88%), Eagle Asset Management Inc. (2.00%), Janus Henderson Group PLC (1.65%) and Geode Capital Management LLC (1.37%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View institutional ownership trends for Omnicell.

Which institutional investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Redwood Investments LLC, AQR Capital Management LLC, PNC Financial Services Group Inc., Kennedy Capital Management Inc., Charles Schwab Investment Management Inc., Falcon Point Capital LLC, and Westwood Holdings Group Inc.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, and Scott Peter Seidelmann. View insider buying and selling activity for Omnicell.

Which institutional investors are buying Omnicell stock?

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Marshall Wace LLP, Credit Suisse AG, Trillium Asset Management LLC, Bank of America Corp DE, WCM Investment Management LLC, Great West Life Assurance Co. Can, and Summit Creek Advisors LLC. View insider buying and selling activity for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $56.85.

How big of a company is Omnicell?

Omnicell has a market capitalization of $2.41 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe. View additional information about Omnicell.

What is Omnicell's official website?

The official website for Omnicell is http://www.omnicell.com/.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  451 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  800
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel